Dulaglutide molecular structure
Dulaglutide molecular structure
Approved
🏋️Weight Loss

Dulaglutide

Also known as: Trulicity, LY2189265

MW

63000.00 Da

CAS

923950-08-7

Routes

1 route

Dulaglutide (Trulicity) is a GLP-1 receptor agonist consisting of a modified GLP-1 analog covalently linked to a modified human IgG4 Fc domain via a small peptide linker. Developed by Eli Lilly, this fusion protein design provides an extended half-life of approximately 5 days through FcRn-mediated recycling, enabling once-weekly dosing. FDA-approved in 2014 for type 2 diabetes. The REWIND trial (2019) was landmark in demonstrating cardiovascular benefit in a broad type 2 diabetes population — not limited to those with established cardiovascular disease — expanding the evidence base for GLP-1RA cardiovascular protection. Trulicity has become one of the most prescribed GLP-1 receptor agonists globally.

Research Use Only— For educational and research purposes only

Research Applications

Type 2 Diabetes (Approved)

FDA-approved for glycemic control and cardiovascular risk reduction. HbA1c reduction of 1.1-1.5%. Weight loss of 2-4 kg.

Cardiovascular Risk Reduction

REWIND trial showed 12% MACE reduction in a broad diabetic population including primary prevention. First GLP-1RA to demonstrate CV benefit across the full risk spectrum.

Mechanism of Action

Dulaglutide activates the GLP-1 receptor through its modified GLP-1 analog moiety. The Fc fusion extends half-life through neonatal Fc receptor (FcRn)-mediated recycling — the same mechanism that gives IgG antibodies their long circulation time. GLP-1R activation produces glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite suppression through standard incretin pathways.

Biological Pathways

Standard GLP-1R signaling: cAMP/PKA for insulin secretion, PI3K/Akt for beta cell survival, central melanocortin for appetite. FcRn-mediated endosomal recycling prevents lysosomal degradation, extending half-life.

Dosage Information

Typical dosage ranges for research applications. Always verify with current literature.
Typical Dose
1,500 mcg
Dose Range
750 - 4,500 mcg
Frequency
Once weekly; start 0.75 mg, titrate by 1.5 mg every 4 weeks to max 4.5 mg
Dosage Calculator
Calculate precise peptide dosages based on your reconstitution parameters
Dosage calculation parameters
Vial size in milligrams
Reconstitution volume in milliliters
Body weight input
Recommended dose per kg
mcg/kg
Desired dose input
mcg

Calculation Results

Concentration
2.5 mg/ml
Dose Volume
0.1 ml0.100 ml
Insulin Syringe
10 units
Doses per Vial
2020 doses @ 250 mcg

Syringe Fill Level (100u syringe)

05010010.0uunits
0u10.0 / 100 units (10%)100u

Protocols

No protocols featuring this peptide yet.

Browse All Protocols

Stability & Storage

Trulicity single-dose pens store at 2-8°C. May be stored at room temperature (up to 30°C) for up to 14 days. Do not freeze. Each pen contains one dose (0.75 mg, 1.5 mg, 3.0 mg, or 4.5 mg).

Side Effects & Precautions

Nausea (12-21%), diarrhea (8-12%), vomiting (6-12%), abdominal pain, decreased appetite. Generally milder GI profile than short-acting GLP-1RAs. Injection site reactions (1-2%). Pancreatitis risk rare. Thyroid C-cell warning. Anti-drug antibodies in ~1% of patients.

Research Use Only. This information is for educational and research purposes only. Not intended for medical advice or self-medication.

Regulatory Status

Approved

FDA-approved (2014) for type 2 diabetes. Cardiovascular risk reduction indication added after REWIND (2020). EMA and global approvals. WADA-prohibited under S2.

Research Studies

Dulaglutide and Cardiovascular Outcomes (REWIND)

Gerstein HC, Colhoun HM, Dagenais GR, et al.

Lancet
2019
View Source

Dulaglutide vs Insulin Glargine in Type 2 Diabetes (AWARD-2)

Giorgino F, Benroubi M, Sun JH, et al.

Diabetes Care
2015
View Source
Dosage Calculator
Calculate reconstitution volumes and injection amounts for Dulaglutide.
Open Calculator
Explore More
Explore more peptides in the Weight Loss category and related research.
View Weight Loss Category